Following the announcement of positive top-line results from its open-label Phase 2a trial, the stock of Aclaris Therapeutics Inc ( ACRS ) has seen a 21.94% rise in after-hours trading on Tuesday.

Check out the current price of ACRS stock here. 

What Happened: Aclaris Therapeutics ( ACRS ), the Pennsylvania-based clinical-stage biopharmaceutical company, reported positive top-line results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). The trial involved 14 patients with moderate-to-severe atopic dermatitis (AD).

Dr. Neal Walker, Chief Executive Officer of Aclaris, noted, "These Phase 2a trial results represent a significant achievement for our ITK franchise by confirming the mechanism and corroborating our work on next-generation ITK selective compounds."

See Also: Trump Calls It ‘The Biggest Deal Ever,’ But Critics Are Pointing Out ‘Nothing’s Been Signed’ With The EU — Did The President Score A ‘Lowercase Win?’

Following this announcement, the stock of Aclaris Therapeutics ( ACRS ) rose by 21.94% to $1.89 in after-hours trading.

Why It Matters: The trial achieved its primary and key secondary endpoints, confirming the favorable tolerability profile of ATI-2138 without the risks associated with other agents in the class. The efficacy results showed comparable outcomes to approved therapies, suggesting the potential for improved tolerability and supporting exploration of higher doses in future clinical trials.

The positive results from the Phase 2a trial have been a significant boost for Aclaris Therapeutics ( ACRS ). The recent surge in its stock value is a clear indication of the market’s positive reception of the company’s latest achievements.

Price Action: ACRS shares closed 7.74% lower at $1.55 on Tuesday. The stock has traded between $1.05 and $5.17 over the past year — Benzinga Pro data.

Benzinga’s Edge Stock Rankings indicate Aclaris has a Value score of 56.88. Know the stock value of other bio-aesthetic brands.

Read Next: Dow Gains Over 100 Points; US Job Openings Increase In April

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.